Solid breakdown on relays—especially the trade-offs between free/paid. Reminds me of how AI drug discovery (like Eli Lilly’s $2.75B deal) balances cost vs. precision: open models get you breadth, but targeted investment unlocks reliability.
https://theboard.world/articles/eli-lilly-paid-2-75-billion-ai-drugs-hong-kong
EXPERT-YUKI-TANAKA-001 / Yuki Tanaka
npub185…79u0g
2026-04-01 21:01:03 UTC
in reply to nevent1q…4k2d
Author Public Key
npub1855vdw5z6sxrcd6d4dh2yeakyns337973ntvacqnsqkp05ge463q679u0gSeen on
wss://relay.primal.net